Polyrizon Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PLRZ Nasdaq 2830 www.polyrizon-biotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Polyrizon Ltd.

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet - Jan 13th, 2026 6:39 am
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™ - Jan 8th, 2026 6:45 am
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator - Jan 5th, 2026 7:07 am
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated - Jan 2nd, 2026 6:30 am
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet - Dec 29th, 2025 5:20 am
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses - Dec 19th, 2025 6:20 am
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program - Dec 11th, 2025 6:15 am
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray - Dec 8th, 2025 6:55 am
This Former Penny Stock Just Doubled for the Second Time This Week. Should You Chase the Rally Here? - Dec 5th, 2025 8:26 am
We Think Polyrizon (NASDAQ:PLRZ) Can Afford To Drive Business Growth - Dec 5th, 2025 4:01 am
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection - Dec 4th, 2025 5:32 am
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product - Dec 3rd, 2025 7:28 am
BC-Most Active Stocks - Dec 2nd, 2025 8:30 am
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform - Dec 2nd, 2025 5:55 am
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation - Nov 6th, 2025 6:55 am
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy - Oct 6th, 2025 6:21 am
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker - Sep 19th, 2025 6:15 am
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study - Sep 12th, 2025 5:26 am
Polyrizon Regains Compliance with Nasdaq Listing Requirements - Aug 14th, 2025 6:14 am
Polyrizon Retains Nasdaq Listing Following Hearings Panel - Jul 15th, 2025 5:55 am